{"id":471077,"date":"2021-04-05T16:08:04","date_gmt":"2021-04-05T20:08:04","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=471077"},"modified":"2021-04-05T16:08:04","modified_gmt":"2021-04-05T20:08:04","slug":"prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/","title":{"rendered":"Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer"},"content":{"rendered":"<h2>\nDr. Garren\u2019s extensive expertise and successful track record of\u00a0advancing neurology and rare disease programs through late-stage development, registration and launch supports Company\u2019s transition to a fully-integrated R&amp;D and commercial business<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">DUBLIN, Ireland, April  05, 2021  (GLOBE NEWSWIRE) &#8212; Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena\u2019s clinical pipeline.<\/p>\n<p align=\"justify\">\u201cHideki brings valuable experience and expertise to our team as we look ahead towards transitioning to a fully integrated research, development and commercial biotechnology company,\u201d said Gene Kinney, PhD, President and Chief Executive Officer. \u201cHis experience leading several late-stage development programs in neurology and rare disease indications through registration and launch is particularly relevant as we advance our pipeline of programs in these areas. We are delighted to welcome him to the team as we prepare for our next stage of growth.\u201d<\/p>\n<p align=\"justify\">\u201cProthena\u2019s impressive scientific platform has advanced a rich pipeline of potentially transformational therapeutics, including several programs that have demonstrated benefit on meaningful clinical endpoints in diseases with highly significant unmet medical needs,\u201d commented Dr. Garren. \u201cI am excited to join the company during this dynamic period of growth and look forward to working as part of this exceptional team with a rich scientific heritage.\u201d<\/p>\n<p align=\"justify\">Dr. Garren joins Prothena from F. Hoffmann-La Roche Ltd. (Roche) &amp; Genentech Inc. where he was Vice President, Global Head of Neuroimmunology, leading Roche\u2019s Neuroimmunology franchise team. A neurologist by training, Dr. Garren was most recently responsible for the Phase 3 clinical programs for Ocrevus for Multiple Sclerosis and Enspryng for Neuromyelitis Optica Spectrum Disorder. Dr. Garren also held the role of Executive Director, Translational Medicine Expert in Neuroscience with Novartis Pharma. Prior to Novartis, Dr. Garren served as Co-Founder, Executive Vice President, Chief Scientific Officer, and Chief Operating Officer of Bayhill Therapeutics, Inc., a company he started in 2002 based on a technology platform he co-invented while at Stanford University.<\/p>\n<p align=\"justify\">Dr. Garren earned his Bachelor of Science from the California Institute of Technology and his MD and PhD from the University of California, Los Angeles (UCLA). He completed his internship in internal medicine at UCLA, and his residency in neurology and fellowship in neuroimmunology at Stanford University.<\/p>\n<p align=\"justify\">\n        <strong>About Prothena<\/strong>\n      <\/p>\n<p align=\"justify\">Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a pipeline of novel investigational therapeutics with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena\u2019s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer\u2019s disease, Parkinson\u2019s disease and a number of other neurodegenerative diseases.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Media<\/strong><br \/>\n        <br \/>Ellen Rose, Head of Communications<br \/>650-922-2405, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2yKC_Q6L6QditSrdT6oqb5aV9J2rMbYKYvPhi3MZjIU2nlmGncjWJ03o-8Mk33phzkRXlN_5eYZnesNlU5rlkyhGTUPv3e7Jq3u5EwltqV8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>ellen.rose@prothena.com<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>Investors<\/strong><br \/>\n        <br \/>Jennifer Zibuda, Director, Investor Relations &amp; Communications<br \/>650-837-8535, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tb6xikhrnircJuHbNZvyzPA5U_O0FOmkWlsWPDefPVFIOSBcB-LPiV-WfROdCJPjYjBJazLI09Jtkv6hVv9Vwf15MfoPTcU3Oq3YyHhq5ARrbhuE7C5DB_8YaS_JoPpD\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>jennifer.zibuda@prothena.com<\/u><\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTE4OSM0MTA0ODI4IzIwMDkwMjk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b28f4d3f-737d-4ac1-a327-abc32272387f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Garren\u2019s extensive expertise and successful track record of\u00a0advancing neurology and rare disease programs through late-stage development, registration and launch supports Company\u2019s transition to a fully-integrated R&amp;D and commercial business DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) &#8212; Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena\u2019s clinical pipeline. \u201cHideki brings valuable experience and expertise to our team as we look ahead towards transitioning to a fully integrated research, development and commercial biotechnology company,\u201d said Gene Kinney, PhD, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-471077","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dr. Garren\u2019s extensive expertise and successful track record of\u00a0advancing neurology and rare disease programs through late-stage development, registration and launch supports Company\u2019s transition to a fully-integrated R&amp;D and commercial business DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) &#8212; Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena\u2019s clinical pipeline. \u201cHideki brings valuable experience and expertise to our team as we look ahead towards transitioning to a fully integrated research, development and commercial biotechnology company,\u201d said Gene Kinney, PhD, &hellip; Continue reading &quot;Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-05T20:08:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTE4OSM0MTA0ODI4IzIwMDkwMjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer\",\"datePublished\":\"2021-04-05T20:08:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/\"},\"wordCount\":558,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTE4OSM0MTA0ODI4IzIwMDkwMjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/\",\"name\":\"Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTE4OSM0MTA0ODI4IzIwMDkwMjk=\",\"datePublished\":\"2021-04-05T20:08:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTE4OSM0MTA0ODI4IzIwMDkwMjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTE4OSM0MTA0ODI4IzIwMDkwMjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer - Market Newsdesk","og_description":"Dr. Garren\u2019s extensive expertise and successful track record of\u00a0advancing neurology and rare disease programs through late-stage development, registration and launch supports Company\u2019s transition to a fully-integrated R&amp;D and commercial business DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) &#8212; Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena\u2019s clinical pipeline. \u201cHideki brings valuable experience and expertise to our team as we look ahead towards transitioning to a fully integrated research, development and commercial biotechnology company,\u201d said Gene Kinney, PhD, &hellip; Continue reading \"Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-05T20:08:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTE4OSM0MTA0ODI4IzIwMDkwMjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer","datePublished":"2021-04-05T20:08:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/"},"wordCount":558,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTE4OSM0MTA0ODI4IzIwMDkwMjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/","name":"Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTE4OSM0MTA0ODI4IzIwMDkwMjk=","datePublished":"2021-04-05T20:08:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTE4OSM0MTA0ODI4IzIwMDkwMjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTE4OSM0MTA0ODI4IzIwMDkwMjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=471077"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471077\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=471077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=471077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=471077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}